31 May 2024
Kanabo Group plc
("Kanabo", the "Group" or the "Company")
Notice of Annual General Meeting
Kanabo Group plc (LSE: KNB), the patient focused healthcare technology and medicinal cannabis company, announces the Notice of Annual General Meeting ("Notice of Meeting") has now been published. The document has been posted to shareholders and is now available to download from the Company's website: https://www.kanabogroup.com/
The Company's Annual General Meeting is scheduled to be held on Thursday, 27 June 2024 at 6th Floor, Saddlers House, 44 Gutter Lane, London, EC2V 6BR. The meeting will commence at 11.00 a.m.
The voting results of all resolutions put before the 2024 AGM will be announced shortly afterwards.
Enquiries:
| Kanabo Group plc Avihu Tamir, Chief Executive Officer Assaf Vardimon, Chief Financial Officer Ian Mattioli, Non-Executive Chair of the Board
| via Peterhouse Capital +44 (0)20 7469 0930 |
| Peterhouse Capital Ltd (Financial Adviser and Broker) Eran Zucker / Lucy Williams / Charles Goodfellow
| +44 (0)20 7469 0930 |
| | |
| | |
About Kanabo Group Plc
Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It, an online clinic focused on chronic pain management that provides patients with secondary care.
With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider. It offers telehealth consultations, prescriptions and tailor-made treatments.
The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.
At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.
Visit www.kanabogroup.com for more information.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.